Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Equilis Prequenza Te er større end risiciene til immunisering af heste, der er seks måneder gamle eller derover, mod hesteinfluenza for at nedsætte de kliniske symptomer og virusudskillelsen efter infektion samt mod stivkrampe for at forebygge dødelighed.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Prequenza Te exceeded the risks for the immunisation of horses from six months of age against equine influenza to reduce clinical signs and virus excretion after infection and against tetanus to prevent mortality.